CA2165663C - Diagnostic reagent stabilizer - Google Patents
Diagnostic reagent stabilizer Download PDFInfo
- Publication number
- CA2165663C CA2165663C CA002165663A CA2165663A CA2165663C CA 2165663 C CA2165663 C CA 2165663C CA 002165663 A CA002165663 A CA 002165663A CA 2165663 A CA2165663 A CA 2165663A CA 2165663 C CA2165663 C CA 2165663C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- succinic acid
- glucose
- salt
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/104998—Glucose, ketone, nitrate standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The inclusion of succinic acid or a salt thereof to stabilize compositions that include glucose oxidase and/or ferricyanide. Typically, the succinic acid or succinic acid salt is included in a diagnostic reagent utilized in test strips or test solutions useful for the analysis of glucose from a fluid sample.
Description
DIAGNOSTIC REAGENT STABILIZER
Field of the Invention This invention relates to the stabilization of compositions that include glucose oxidase and/or ferricyanide.
s Background of the Invention Compositions, such as diagnostic reagent compositions, that include glucose oxidase or ferricyanide have poor stability due to the tendency for glucose oxidase and ferricyanide to degrade.
Succinic acid and some salts of succinic acid have been used in the ~o following references as a stabilizing agent (stabilizing, for example, a detergent composition) or a chelating agent:
Bos-kamn, U.S. Patent No. 4,532,064, issued July 30, 1984;
Thomas, International Patent Application Publication No. WO 86/04610, published August 14, 1986;
Ramachandran et al., U.S. Patent No. 4,900,475, issued February 13, 1990;
Dormal et al., U.S. Patent No. 4,529,525, issued July 16, 1985;
D nn , European Patent Specification EP O 072 581 B1, issued April 8, 1987; JP 63202381, published August 22, 1988; and JP 57138389, published August 26, 1982.
ao None of these references discloses the use of succinic acid or a salt thereof to stabilize an aqueous or dried reagent that includes glucose oxidase and/or ferricyanide.
Summa~r r of the Invention The invention is a stable composition of matter useful as a diagnostic as reagent for the analysis of glucose from a fluid sample and a process for stabilizing compositions that include glucose oxidase and/or ferricyanide.
The invention is based upon the surprising result that the inclusion of succinic acid or a salt thereof will stabilize a composition that includes glucose oxidase and/or ferricyanide.
Preferably, the succinic acid or a salt thereof is disodium succinate, which is utilized in a diagnostic reagent useful far the analysis of glucose in a biosensor. The reagent is preferably made up in an aqueous slurry that includes glucose oxidase, potassium phosphate (buffer), potassium s ferricyanide (a redox mediator), a dispersant and crystallization inhibitor, such as AVICEL (trade-mark) RC - 591 F, which is a blend of 88% microcrystalline cellulose and 12% sodium carboxymethylcellulose, a small amount of hydroxyethylcellulose, a surfactant (such as TRITON (trade-mark) X-100 surfactant, which includes various polyoxyethylene ethers), and water. After to mixing, the resulting slurry may be coated onto the surface of working and counter electrodes in an electrochemical biosensor, dried, and subsequently utilized in the measurement of glucose from a fluid sample, as described herein.
More broadly, succinic acid or a salt thereof may stabilize other is compositions of matter that include either glucose oxidase and/or ferricyanide, such as various kinds of glucose test reagents that utilize either glucose oxidase and/or ferricyanide.
Brief Description of the Drawings Fig. 1 is a schematic top view of a biosensor which may utilize the 2o stable composition of the present invention.
Fig. 2 is a schematic elevation of the biosensor of Fig. 1 along lines 2-2, and including the stable composition of the present invention and a cover mesh.
Fig. 3 is a schematic tap view of the biosensor of Fig. 2.
Description of the Invention A specific embodiment of the present invention will first be described.
This specific embodiment utilizes a reagent that has been made more stable WO 95/00662 ~ ~ ~ ~ 6 6 3 3 PCT/US94/07223 by the inclusion of disodium succinate. A protocol for making the reagent is as follows:
Step 1 - Prepare 1 liter (in a volumetric flask) of a buffer/NATROSOL mixture by adding 1.2 grams (g) s hydroxyethylcellulose (sold under the mark NATROSOL
250 M NF, available from Aqualon Company) to 0.74 molar (M) aqueous potassium phosphate and 26.4 g dibasic potassium phosphate at pH 6.25. Allow the buffer/NATROSOL mixture to stir and swell for 3 hours.
Step 2 - Prepare an AVICEL mixture by stirring 14 g AVICEL
RC-591 F dispersant and crystallization inhibitor (available from FMC Corporation) and 504.8 g water for 20 minutes.
Step 3 - Prepare a TRITON mixture by adding 0.5 g TRITON X-100 surfactant to 514.6 g of the buffer/NATROSOL
mixture and stir for 15 minutes.
Step 4 - While stirring, add the total TRITON mixture dropwise with a dropwise addition funnel or buret to the total AVICEL
mixture. Once addition is complete, continue stirring ao overnight.
Step 5 - To the mixture resulting from Step 4, add, while stirring, 98.8 g potassium ferricyanide. (Add a little potassium ferricyanide at a time to allow the potassium ferricyanide to dissolve as added.) 25 Step 6 - Stir the resulting mixture of Step 5 for 20 minutes.
Step 7 - Adjust the pH of the mixture resulting from Step 6 to 6.25 WO 95/00662 ~ ~ ~ ~ PCT/US94107223 by adding potassium hydroxide.
Step 8 - To the resulting mixture of Step 7, add 9.2 g glucose oxidase (218.5 ortho-dianisidine units per milligram (mg) from Biozyme) and stir at least 20 minutes.
s Step 9 - To the resulting mixture of Step 8, add 10 g (37 millimoles (mmol)) disodium succinate hexahydrate and stir at least 20 minutes.
Step 10 - Filter the resulting mixture of Step 9 through a 100 micron sieve bag to remove any AVICEL clumping. The ~o filtrate is the resulting reagent composition 11 (see Fig.2), which is added to the electrode surfaces of the electrochemical biosensor, described below, and is then dried. (Before drying, this composition is 0.37 molar in phosphate buffer. A more preferred formulation is made 0.25 molar in phosphate buffer. The final activity of glucose oxidase in the composition is preferably 1.57 tetramethylbenzidine (TMB) megaunits per liter of composition before drying.) zo Referring to FIGS. 1 through 3, biosensor 1 comprises first and second electrically insulating layers 2 and 3, respectively. Any useful insulating material will be suitable. Typically, plastics, such as vinyl polymers and polyimides provide the electrical and structural properties which are desired.
25 The biosensor shown in FIGS. 1 through 3 is intended to be mass produced from rolls of material, necessitating the selection of a material which is sufficiently flexible for roll processing and at the same time sufficiently stiff to give a useful stiffness to the finished biosensor.
Layers 2 and 3 may be of any useful thickness. In a preferred embodiment, layer 2 is about 360 microns thick and layer 3 is about 250 5 microns thick.
Working electrode 4 and counter electrode 5 are preferably deposited on a backing of insulator material 7, such as polyimide, to reduce the possibility of tearing the electrode before it is affixed to layer 2. Working electrode 4 and counter electrode 5 are substantially the same size and are made of the same electrically conducting material. Examples of electrically conducting materials that may be used are palladium, platinum, gold, silver, carbon, titanium, and copper. Noble metals are preferred because they provide a more constant, reproducible electrode surface area. Palladium is particularly preferred because it is one of the more difficult noble metals to ~5 oxidize and because it is a relatively inexpensive noble metal. Silver is not preferred because it is more readily oxidized by air than the other noble metals listed above. Preferably, electrodes 4 and 5 are about 0.1 micron thick and backing 7 is about 25 microns thick (commercially available from Courtalls-Andus Performance Films in California and Southwall Technologies, ao Inc.) (Fig 2).
Electrodes 4 and 5 must be sufficiently separated so that the electrochemical events at one electrode do not interfere with the electrochemical events at the other electrode. The preferred distance between electrodes 4 and 5 is about 1.2 millimeters (mm).
25 In the preferred embodiment, electrodes 4 and 5, affixed to backing 7, are unspooled from reels and attached to layer 2 by the use of hot melt 6 ~ S ~ PCT/US94107223 adhesive (not shown). Electrodes 4 and 5 also preferably extend from one end of layer 2 to the other end in parallel configuration. (Fig. 1 ) Insulating layer 3 is fixed on top of layer 2 and electrodes 4 and 5 by the use of hot melt adhesive (not shown). Layer 3 includes cutout portion 8, s which defines reagent well 9 and exposes substantially equal surface areas of electrodes 4 and 5. In the preferred embodiment, cutout 8 is 4 mm by 6 mm and electrodes 4 and 5 are each 1.5 mm in width. Therefore a surface area of about 6 mm2 is exposed for each of the two electrodes.
Biosensor 1 also includes a power source (not shown) in electrical connection with the working and counter electrodes and a current measuring meter (not shown) which is also in electrical connection with the working and counter electrodes.
Biosensor reagent 11 (Fig. 2) is placed in well 9 so that it covers substantially all of exposed surfaces 10 of electrodes 4 and 5 and preferably covers the exposed surface of layer 2 between the electrodes.
In the embodiment described above, which is useful for glucose determination from a fluid sample, 6 microliters (~I) of reagent 11 made by the above-stated protocol is added to well 9 formed by cutout 8. This amount of reagent 11 will substantially cover surface areas 10 on both electrodes ao (Figs. 1 and 2) and will also contain a sufficient amount of reagent to perform an assay for glucose (described below).
Reagent 11 is then dried by heating at about 50° C for about 3 minutes. Drying removes at least about 90% of the water content of the reagent, thereby resulting in a dried reagent.
25 After drying, a polyester or nylon mesh 13 (Figs. 2 and 3) is preferably placed on top of the dried reagent to aid in preventing loss of reagent from 21656 ~
the biosensor during shipping and handling and to aid in minimizing human contamination from the reagent. Mesh 13 is affixed to the biosensor by adhesive tape 14, which includes hole 15. (Figs 2. and 3) Hole 15 is the target area for adding a sample containing an analyte, such as glucose, to be s measured by the biosensor. (Fig. 3) After drying the reagent and affixing the mesh, the roll-formed biosensors are separated by die punching to form discrete biosensors, which are used in conjunction with a power source (i.e., a battery) in electrical connection with the working and counter electrodes and a meter for measuring io electrical current.
The meter referred to above will normally be adapted to apply an algorithm to the current measurement, whereby an analyte concentration is provided and visually displayed. Improvements in such a power source and meter are the subject of commonly assigned U.S. Patent Number 4,963,814 is issued October 16, 1990, U.S. Patent No. 4,999,632, issued March 12, 1991, U.S. Patent No. 4,999,582, issued March 12, 1991, and U.S. Patent Application Serial No. 07/451,305 (filed December 15, 1989; Notice of Allowance issued April 19, 1993).
For easy electrical connection of the power source and meter, 2o additional cutout portion 12 (Figs. 1 through 3), exposing portions of the working and counter electrodes, is preferably provided in the biosensor device.
The biosensor setup described above including the reagent, may be used in conjunction with the power source and meter to measure glucose from a fluid sample, such as a blood sample.
A
WO 95/00662 ~ ~ PCT/US94/07223 When a blood sample (20 microliters (~I) is sufficient) is added to reagent well 9, the reagent 11 is rehydrated, thereby solubilizing potassium ferricyanide, glucose oxidase (GOD), potassium phosphate buffer, disodium succinate and surfactant. If glucose is present in the blood sample, the s following chemical reaction occurs:
GOD
glucose + ferricyanide ------------> gluconic acid + ferrocyanide.
An incubation period (20 seconds is sufficient) for this reaction is ~o allowed in order to let this reaction proceed to an end point, thereby building up a significant amount of ferrocyanide. Next, a potential difference is applied (by the power source) between working and counter electrodes sufficient to cause diffusion limited electrooxidation of ferrocyanide (converting the ferrocyanide to ferricyanide) at the surface of the working electrode. (About 300 millivolts potential difference is preferred.) The resulting diffusion limited current may be correlated to the amount of glucose in the blood sample.
The preferred reagent formulation, recited above, was optimized for both stability and performance, as reflected by good assay precision, in a ao glucose assay performed with the above described biosensor strip. Stability studies show that this reagent formulation will have a stability greater than years. A reagent made by the protocol specified above was also stabilized when the included amount of disodium succinate hexahydrate varied from about 1/2% weight/volume of reagent slurry (about 18 and 1/2 millimolar (mM
as in succinate) to about 1 and 1/2% weight/volume of reagent slurry (about 55 mM in succinate). Further decreasing the amount of disodium succinate in the reagent below about 18 and 1/2 mM will cause further decreases in 216~ss ~
reagent stability. These further decreases in reagent stability may be described as a "tailing off' effect, wherein reagent stability decreases until there is little, if any, stability. Increasing the amount of the disodium succinate above about 55 mM in the reagent will further increase reagent stability, but s only up to some upper limit where further addition of disodium succinate will not increase stability of the reagent.
The above reagent is stabilized by the inclusion of disodium succinate.
Disodium succinate stabilizes both ferricyanide and glucose oxidase, thereby greatly retarding the decomposition of these reagent components and the io resulting degradation of the reagent. Although the invention has been illustrated with disodium succinate, compositions that include either ferricyanide or glucose oxidase should also be stabilized by the inclusion of other succinate salts and by the inclusion of succinic acid itself.
Stabilization will be observed irrespective of the reagent matrix. The reagent matrix may be Is an aqueous slurry, as specified in the above protocol before drying of the reagent on the biosensor strip, an aqueous solution, or a dried matrix, such as the above specified reagent after drying on the biosensor strip, or a reagent incorporated into a film, membrane, or porous matrix, such as nylon nonwoven mesh.
The present invention may be applied to a wide variety of analytical and diagnostic reagents and apparatus that include either glucose oxidase or ferricyanide or both glucose oxidase and ferricyanide. Succinic acid or a salt thereof may be included in the reagents and apparatus described in the 2s following references:
Nankai et al., U.S. Patent No. 4,431,507, issued February 14,1984;
Nankai et al., U.S. Patent No. 5,120,420, issued June 9, 1992;
Woaoman, U.S. Patent No. 5,030,310, issued July 9, 1991;
s Senda et al., U.S. Patent No. 4,820,399, issued April 11, 1989;
Nankai et al., U.S. Patent No. 4,897,173, issued January 30, 1990;
Hiaains et al., U.S. Patent No. 4,545,382, issued October 8, 1985;
Mindt et al., U.S. Patent No. 3,838,033, issued September 24, 1974 Nakamura et al., U.S. Patent No. 4,224,125, issued September 23, 1980;
Hoenes et al., U.S. Patent No. 5,122,244, issued June 16, 1992;
i5 Higgins et al., U.S. Patent No. 4,711,245, issued December 8, 1987;
Davis et al., U.S. Patent No. 4,758,323, issued July 19, 1988;
Nakamura et al., U.S. Patent No. 4,392,933, issued July 12, 1983;
McNeil et al., U.S. Patent No. 4,830,959, issued May 16, 1989;
ao Phillips et al., U.S. Patent No. 5,049,487, issued September 17, 1991;
Takizawa et al., U.S. Patent No. 4,894,137, issued January 16, 1990;
Kawaguri et al., U.S. Patent No. 5,171,689, z s issued December 15, 1992;
Freitaa, U.S. Patent No. 4,929,545, issued May 29, 1990;
21s5ss 3 and Philli s et al., U.S. Patent No. 5,059,394, issued October 22, 1991.
(In some of these references, glucose oxidase has been cross-linked by s chemical treatment (for example, by treatment with glutaraldehyde) or glucose oxidase has been covalently bound to the surface of an electrode. In such cases, the inclusion of succinic acid or a salt thereof may not additionally stabilize the reagent.) to The present invention has been disclosed in the above teachings and drawings with sufficient clarity and conciseness to enable one skilled in the art to make and use the invention, to know the best mode for carrying out the invention, and to distinguish if from other inventions and from what is old.
Many variations and obvious adaptations of the invention will readily come to mind, and these are intended to be contained within the scope of the invention as claimed below.
Field of the Invention This invention relates to the stabilization of compositions that include glucose oxidase and/or ferricyanide.
s Background of the Invention Compositions, such as diagnostic reagent compositions, that include glucose oxidase or ferricyanide have poor stability due to the tendency for glucose oxidase and ferricyanide to degrade.
Succinic acid and some salts of succinic acid have been used in the ~o following references as a stabilizing agent (stabilizing, for example, a detergent composition) or a chelating agent:
Bos-kamn, U.S. Patent No. 4,532,064, issued July 30, 1984;
Thomas, International Patent Application Publication No. WO 86/04610, published August 14, 1986;
Ramachandran et al., U.S. Patent No. 4,900,475, issued February 13, 1990;
Dormal et al., U.S. Patent No. 4,529,525, issued July 16, 1985;
D nn , European Patent Specification EP O 072 581 B1, issued April 8, 1987; JP 63202381, published August 22, 1988; and JP 57138389, published August 26, 1982.
ao None of these references discloses the use of succinic acid or a salt thereof to stabilize an aqueous or dried reagent that includes glucose oxidase and/or ferricyanide.
Summa~r r of the Invention The invention is a stable composition of matter useful as a diagnostic as reagent for the analysis of glucose from a fluid sample and a process for stabilizing compositions that include glucose oxidase and/or ferricyanide.
The invention is based upon the surprising result that the inclusion of succinic acid or a salt thereof will stabilize a composition that includes glucose oxidase and/or ferricyanide.
Preferably, the succinic acid or a salt thereof is disodium succinate, which is utilized in a diagnostic reagent useful far the analysis of glucose in a biosensor. The reagent is preferably made up in an aqueous slurry that includes glucose oxidase, potassium phosphate (buffer), potassium s ferricyanide (a redox mediator), a dispersant and crystallization inhibitor, such as AVICEL (trade-mark) RC - 591 F, which is a blend of 88% microcrystalline cellulose and 12% sodium carboxymethylcellulose, a small amount of hydroxyethylcellulose, a surfactant (such as TRITON (trade-mark) X-100 surfactant, which includes various polyoxyethylene ethers), and water. After to mixing, the resulting slurry may be coated onto the surface of working and counter electrodes in an electrochemical biosensor, dried, and subsequently utilized in the measurement of glucose from a fluid sample, as described herein.
More broadly, succinic acid or a salt thereof may stabilize other is compositions of matter that include either glucose oxidase and/or ferricyanide, such as various kinds of glucose test reagents that utilize either glucose oxidase and/or ferricyanide.
Brief Description of the Drawings Fig. 1 is a schematic top view of a biosensor which may utilize the 2o stable composition of the present invention.
Fig. 2 is a schematic elevation of the biosensor of Fig. 1 along lines 2-2, and including the stable composition of the present invention and a cover mesh.
Fig. 3 is a schematic tap view of the biosensor of Fig. 2.
Description of the Invention A specific embodiment of the present invention will first be described.
This specific embodiment utilizes a reagent that has been made more stable WO 95/00662 ~ ~ ~ ~ 6 6 3 3 PCT/US94/07223 by the inclusion of disodium succinate. A protocol for making the reagent is as follows:
Step 1 - Prepare 1 liter (in a volumetric flask) of a buffer/NATROSOL mixture by adding 1.2 grams (g) s hydroxyethylcellulose (sold under the mark NATROSOL
250 M NF, available from Aqualon Company) to 0.74 molar (M) aqueous potassium phosphate and 26.4 g dibasic potassium phosphate at pH 6.25. Allow the buffer/NATROSOL mixture to stir and swell for 3 hours.
Step 2 - Prepare an AVICEL mixture by stirring 14 g AVICEL
RC-591 F dispersant and crystallization inhibitor (available from FMC Corporation) and 504.8 g water for 20 minutes.
Step 3 - Prepare a TRITON mixture by adding 0.5 g TRITON X-100 surfactant to 514.6 g of the buffer/NATROSOL
mixture and stir for 15 minutes.
Step 4 - While stirring, add the total TRITON mixture dropwise with a dropwise addition funnel or buret to the total AVICEL
mixture. Once addition is complete, continue stirring ao overnight.
Step 5 - To the mixture resulting from Step 4, add, while stirring, 98.8 g potassium ferricyanide. (Add a little potassium ferricyanide at a time to allow the potassium ferricyanide to dissolve as added.) 25 Step 6 - Stir the resulting mixture of Step 5 for 20 minutes.
Step 7 - Adjust the pH of the mixture resulting from Step 6 to 6.25 WO 95/00662 ~ ~ ~ ~ PCT/US94107223 by adding potassium hydroxide.
Step 8 - To the resulting mixture of Step 7, add 9.2 g glucose oxidase (218.5 ortho-dianisidine units per milligram (mg) from Biozyme) and stir at least 20 minutes.
s Step 9 - To the resulting mixture of Step 8, add 10 g (37 millimoles (mmol)) disodium succinate hexahydrate and stir at least 20 minutes.
Step 10 - Filter the resulting mixture of Step 9 through a 100 micron sieve bag to remove any AVICEL clumping. The ~o filtrate is the resulting reagent composition 11 (see Fig.2), which is added to the electrode surfaces of the electrochemical biosensor, described below, and is then dried. (Before drying, this composition is 0.37 molar in phosphate buffer. A more preferred formulation is made 0.25 molar in phosphate buffer. The final activity of glucose oxidase in the composition is preferably 1.57 tetramethylbenzidine (TMB) megaunits per liter of composition before drying.) zo Referring to FIGS. 1 through 3, biosensor 1 comprises first and second electrically insulating layers 2 and 3, respectively. Any useful insulating material will be suitable. Typically, plastics, such as vinyl polymers and polyimides provide the electrical and structural properties which are desired.
25 The biosensor shown in FIGS. 1 through 3 is intended to be mass produced from rolls of material, necessitating the selection of a material which is sufficiently flexible for roll processing and at the same time sufficiently stiff to give a useful stiffness to the finished biosensor.
Layers 2 and 3 may be of any useful thickness. In a preferred embodiment, layer 2 is about 360 microns thick and layer 3 is about 250 5 microns thick.
Working electrode 4 and counter electrode 5 are preferably deposited on a backing of insulator material 7, such as polyimide, to reduce the possibility of tearing the electrode before it is affixed to layer 2. Working electrode 4 and counter electrode 5 are substantially the same size and are made of the same electrically conducting material. Examples of electrically conducting materials that may be used are palladium, platinum, gold, silver, carbon, titanium, and copper. Noble metals are preferred because they provide a more constant, reproducible electrode surface area. Palladium is particularly preferred because it is one of the more difficult noble metals to ~5 oxidize and because it is a relatively inexpensive noble metal. Silver is not preferred because it is more readily oxidized by air than the other noble metals listed above. Preferably, electrodes 4 and 5 are about 0.1 micron thick and backing 7 is about 25 microns thick (commercially available from Courtalls-Andus Performance Films in California and Southwall Technologies, ao Inc.) (Fig 2).
Electrodes 4 and 5 must be sufficiently separated so that the electrochemical events at one electrode do not interfere with the electrochemical events at the other electrode. The preferred distance between electrodes 4 and 5 is about 1.2 millimeters (mm).
25 In the preferred embodiment, electrodes 4 and 5, affixed to backing 7, are unspooled from reels and attached to layer 2 by the use of hot melt 6 ~ S ~ PCT/US94107223 adhesive (not shown). Electrodes 4 and 5 also preferably extend from one end of layer 2 to the other end in parallel configuration. (Fig. 1 ) Insulating layer 3 is fixed on top of layer 2 and electrodes 4 and 5 by the use of hot melt adhesive (not shown). Layer 3 includes cutout portion 8, s which defines reagent well 9 and exposes substantially equal surface areas of electrodes 4 and 5. In the preferred embodiment, cutout 8 is 4 mm by 6 mm and electrodes 4 and 5 are each 1.5 mm in width. Therefore a surface area of about 6 mm2 is exposed for each of the two electrodes.
Biosensor 1 also includes a power source (not shown) in electrical connection with the working and counter electrodes and a current measuring meter (not shown) which is also in electrical connection with the working and counter electrodes.
Biosensor reagent 11 (Fig. 2) is placed in well 9 so that it covers substantially all of exposed surfaces 10 of electrodes 4 and 5 and preferably covers the exposed surface of layer 2 between the electrodes.
In the embodiment described above, which is useful for glucose determination from a fluid sample, 6 microliters (~I) of reagent 11 made by the above-stated protocol is added to well 9 formed by cutout 8. This amount of reagent 11 will substantially cover surface areas 10 on both electrodes ao (Figs. 1 and 2) and will also contain a sufficient amount of reagent to perform an assay for glucose (described below).
Reagent 11 is then dried by heating at about 50° C for about 3 minutes. Drying removes at least about 90% of the water content of the reagent, thereby resulting in a dried reagent.
25 After drying, a polyester or nylon mesh 13 (Figs. 2 and 3) is preferably placed on top of the dried reagent to aid in preventing loss of reagent from 21656 ~
the biosensor during shipping and handling and to aid in minimizing human contamination from the reagent. Mesh 13 is affixed to the biosensor by adhesive tape 14, which includes hole 15. (Figs 2. and 3) Hole 15 is the target area for adding a sample containing an analyte, such as glucose, to be s measured by the biosensor. (Fig. 3) After drying the reagent and affixing the mesh, the roll-formed biosensors are separated by die punching to form discrete biosensors, which are used in conjunction with a power source (i.e., a battery) in electrical connection with the working and counter electrodes and a meter for measuring io electrical current.
The meter referred to above will normally be adapted to apply an algorithm to the current measurement, whereby an analyte concentration is provided and visually displayed. Improvements in such a power source and meter are the subject of commonly assigned U.S. Patent Number 4,963,814 is issued October 16, 1990, U.S. Patent No. 4,999,632, issued March 12, 1991, U.S. Patent No. 4,999,582, issued March 12, 1991, and U.S. Patent Application Serial No. 07/451,305 (filed December 15, 1989; Notice of Allowance issued April 19, 1993).
For easy electrical connection of the power source and meter, 2o additional cutout portion 12 (Figs. 1 through 3), exposing portions of the working and counter electrodes, is preferably provided in the biosensor device.
The biosensor setup described above including the reagent, may be used in conjunction with the power source and meter to measure glucose from a fluid sample, such as a blood sample.
A
WO 95/00662 ~ ~ PCT/US94/07223 When a blood sample (20 microliters (~I) is sufficient) is added to reagent well 9, the reagent 11 is rehydrated, thereby solubilizing potassium ferricyanide, glucose oxidase (GOD), potassium phosphate buffer, disodium succinate and surfactant. If glucose is present in the blood sample, the s following chemical reaction occurs:
GOD
glucose + ferricyanide ------------> gluconic acid + ferrocyanide.
An incubation period (20 seconds is sufficient) for this reaction is ~o allowed in order to let this reaction proceed to an end point, thereby building up a significant amount of ferrocyanide. Next, a potential difference is applied (by the power source) between working and counter electrodes sufficient to cause diffusion limited electrooxidation of ferrocyanide (converting the ferrocyanide to ferricyanide) at the surface of the working electrode. (About 300 millivolts potential difference is preferred.) The resulting diffusion limited current may be correlated to the amount of glucose in the blood sample.
The preferred reagent formulation, recited above, was optimized for both stability and performance, as reflected by good assay precision, in a ao glucose assay performed with the above described biosensor strip. Stability studies show that this reagent formulation will have a stability greater than years. A reagent made by the protocol specified above was also stabilized when the included amount of disodium succinate hexahydrate varied from about 1/2% weight/volume of reagent slurry (about 18 and 1/2 millimolar (mM
as in succinate) to about 1 and 1/2% weight/volume of reagent slurry (about 55 mM in succinate). Further decreasing the amount of disodium succinate in the reagent below about 18 and 1/2 mM will cause further decreases in 216~ss ~
reagent stability. These further decreases in reagent stability may be described as a "tailing off' effect, wherein reagent stability decreases until there is little, if any, stability. Increasing the amount of the disodium succinate above about 55 mM in the reagent will further increase reagent stability, but s only up to some upper limit where further addition of disodium succinate will not increase stability of the reagent.
The above reagent is stabilized by the inclusion of disodium succinate.
Disodium succinate stabilizes both ferricyanide and glucose oxidase, thereby greatly retarding the decomposition of these reagent components and the io resulting degradation of the reagent. Although the invention has been illustrated with disodium succinate, compositions that include either ferricyanide or glucose oxidase should also be stabilized by the inclusion of other succinate salts and by the inclusion of succinic acid itself.
Stabilization will be observed irrespective of the reagent matrix. The reagent matrix may be Is an aqueous slurry, as specified in the above protocol before drying of the reagent on the biosensor strip, an aqueous solution, or a dried matrix, such as the above specified reagent after drying on the biosensor strip, or a reagent incorporated into a film, membrane, or porous matrix, such as nylon nonwoven mesh.
The present invention may be applied to a wide variety of analytical and diagnostic reagents and apparatus that include either glucose oxidase or ferricyanide or both glucose oxidase and ferricyanide. Succinic acid or a salt thereof may be included in the reagents and apparatus described in the 2s following references:
Nankai et al., U.S. Patent No. 4,431,507, issued February 14,1984;
Nankai et al., U.S. Patent No. 5,120,420, issued June 9, 1992;
Woaoman, U.S. Patent No. 5,030,310, issued July 9, 1991;
s Senda et al., U.S. Patent No. 4,820,399, issued April 11, 1989;
Nankai et al., U.S. Patent No. 4,897,173, issued January 30, 1990;
Hiaains et al., U.S. Patent No. 4,545,382, issued October 8, 1985;
Mindt et al., U.S. Patent No. 3,838,033, issued September 24, 1974 Nakamura et al., U.S. Patent No. 4,224,125, issued September 23, 1980;
Hoenes et al., U.S. Patent No. 5,122,244, issued June 16, 1992;
i5 Higgins et al., U.S. Patent No. 4,711,245, issued December 8, 1987;
Davis et al., U.S. Patent No. 4,758,323, issued July 19, 1988;
Nakamura et al., U.S. Patent No. 4,392,933, issued July 12, 1983;
McNeil et al., U.S. Patent No. 4,830,959, issued May 16, 1989;
ao Phillips et al., U.S. Patent No. 5,049,487, issued September 17, 1991;
Takizawa et al., U.S. Patent No. 4,894,137, issued January 16, 1990;
Kawaguri et al., U.S. Patent No. 5,171,689, z s issued December 15, 1992;
Freitaa, U.S. Patent No. 4,929,545, issued May 29, 1990;
21s5ss 3 and Philli s et al., U.S. Patent No. 5,059,394, issued October 22, 1991.
(In some of these references, glucose oxidase has been cross-linked by s chemical treatment (for example, by treatment with glutaraldehyde) or glucose oxidase has been covalently bound to the surface of an electrode. In such cases, the inclusion of succinic acid or a salt thereof may not additionally stabilize the reagent.) to The present invention has been disclosed in the above teachings and drawings with sufficient clarity and conciseness to enable one skilled in the art to make and use the invention, to know the best mode for carrying out the invention, and to distinguish if from other inventions and from what is old.
Many variations and obvious adaptations of the invention will readily come to mind, and these are intended to be contained within the scope of the invention as claimed below.
Claims (17)
1. A process for stabilizing a slurry composition containing at least one of glucose oxidase and ferricyanide, comprising:
adding a sufficient amount of succinic acid or a salt thereof to the slurry composition to stabilize the composition.
adding a sufficient amount of succinic acid or a salt thereof to the slurry composition to stabilize the composition.
2. The process of claim 1, wherein the concentration of succinic acid or a salt thereof is from about 18 1 /2 millimolar to about 55 millimolar.
3. The process of claim 1, wherein the concentration of succinic acid or a salt thereof is about 37 millimolar.
4. The process of claim 1, 2 or 3, wherein the succinic acid or a salt thereof is disodium succinate.
5. The process of claim 1, 2, 3 or 4, wherein the composition includes water, a dispersant and crystallization inhibitor in sufficient amount to form a slurry, and a buffer in sufficient amount to provide and maintain a pH at which glucose oxidase will catalyze the oxidation of glucose.
6. The process of claim 5, wherein the composition further includes a surfactant in sufficient amount to aid in rehydrating the composition with an aqueous sample after the slurry has been dried to form a dry reagent useful for the analysis of glucose in the sample.
7. The process of claim 6, wherein the succinic acid or a salt thereof is about 37 millimolar.
8. The process of any one of claims 1 to 7, wherein said slurry composition contains glucose oxidase.
9. The process of any one of claims 1 to 7, wherein said slurry composition contains ferricyanide.
10. A composition of matter comprising:
glucose oxidase in an aqueous medium, or in a dried matrix; and succinic acid or a salt thereof in a concentration from about 18.5 millimolar to about 55 millimolar to stabilize the composition of matter.
glucose oxidase in an aqueous medium, or in a dried matrix; and succinic acid or a salt thereof in a concentration from about 18.5 millimolar to about 55 millimolar to stabilize the composition of matter.
11. The composition of claim 10, further comprising:
a buffer in sufficient amount to provide and maintain a pH at which glucose oxidase will catalyze the oxidation of glucose.
a buffer in sufficient amount to provide and maintain a pH at which glucose oxidase will catalyze the oxidation of glucose.
12. The composition of claim 10 or 11, further comprising:
a ferricyanide in sufficient amount to function as a redox mediator in the catalytic oxidation of glucose.
a ferricyanide in sufficient amount to function as a redox mediator in the catalytic oxidation of glucose.
13. The composition of claim 10, 11 or 12, wherein the glucose oxidase is in the dried matrix and the composition further comprises a surfactant in sufficient amount to aid in rehydrating the composition when an aqueous sample is added to the dried matrix.
14. The composition of claim 10, 11 or 12, wherein the glucose oxidase is in the aqueous medium formed by combining water and a dispersant and crystallization inhibitor.
15. The composition of claim 14, further comprising:
a surfactant in sufficient amount to aid in rehydrating the composition with an aqueous sample after the composition has been dried to form a dry reagent useful for the analysis of glucose in the aqueous sample.
a surfactant in sufficient amount to aid in rehydrating the composition with an aqueous sample after the composition has been dried to form a dry reagent useful for the analysis of glucose in the aqueous sample.
16. The composition of claim 14 or 15, wherein the concentration of succinic acid or a salt thereof is about 37 millimolar.
17. The composition of claim 14, 15 or 16, wherein the succinic acid or a salt thereof is disodium succinate.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8026393A | 1993-06-21 | 1993-06-21 | |
US08/080,263 | 1993-06-21 | ||
PCT/US1994/007223 WO1995000662A1 (en) | 1993-06-21 | 1994-06-21 | Diagnostic reagent stabilizer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2165663A1 CA2165663A1 (en) | 1995-01-05 |
CA2165663C true CA2165663C (en) | 2004-11-23 |
Family
ID=22156257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002165663A Expired - Lifetime CA2165663C (en) | 1993-06-21 | 1994-06-21 | Diagnostic reagent stabilizer |
Country Status (9)
Country | Link |
---|---|
US (1) | US5627075A (en) |
EP (1) | EP0705348B1 (en) |
JP (1) | JP3839470B2 (en) |
AU (1) | AU680520B2 (en) |
CA (1) | CA2165663C (en) |
DE (3) | DE9422352U1 (en) |
ES (1) | ES2154249T3 (en) |
NZ (1) | NZ268301A (en) |
WO (1) | WO1995000662A1 (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358722B1 (en) | 1994-04-25 | 2002-03-19 | Roche Vitamins, Inc. | Heat tolerant phytases |
US6699704B1 (en) | 1994-04-25 | 2004-03-02 | Roche Vitamins Inc. | Heat tolerant phytases |
WO1998020348A1 (en) * | 1996-11-08 | 1998-05-14 | Mercury Diagnostics, Inc. | Opaque reaction matrix for the analysis of whole blood |
CA2231948C (en) | 1997-03-25 | 2010-05-18 | F. Hoffmann-La Roche Ag | Modified phytases |
NZ330940A (en) | 1997-07-24 | 2000-02-28 | F | Production of consensus phytases from fungal origin using computer programmes |
JP3375040B2 (en) | 1997-07-29 | 2003-02-10 | 松下電器産業株式会社 | Substrate quantification method |
EP0969089A1 (en) * | 1998-06-29 | 2000-01-05 | F. Hoffmann-La Roche Ag | Phytase formulation |
AU760737B2 (en) * | 1998-06-29 | 2003-05-22 | Dsm Ip Assets B.V. | Phytase formulation |
US20050103624A1 (en) | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
US6413213B1 (en) | 2000-04-18 | 2002-07-02 | Roche Diagnostics Corporation | Subscription based monitoring system and method |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US6821410B2 (en) * | 2001-03-07 | 2004-11-23 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method of substrate quantification |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7537571B2 (en) | 2001-06-12 | 2009-05-26 | Pelikan Technologies, Inc. | Integrated blood sampling analysis system with multi-use sampling module |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
JP4209767B2 (en) | 2001-06-12 | 2009-01-14 | ペリカン テクノロジーズ インコーポレイテッド | Self-optimized cutting instrument with adaptive means for temporary changes in skin properties |
US7344894B2 (en) | 2001-10-16 | 2008-03-18 | Agilent Technologies, Inc. | Thermal regulation of fluidic samples within a diagnostic cartridge |
US20030077702A1 (en) * | 2001-10-23 | 2003-04-24 | Rajiv Shah | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
EP1459059A4 (en) * | 2001-11-26 | 2005-01-19 | Ischemia Tech Inc | Electrochemical detection of ischemia |
US7374544B2 (en) | 2002-04-19 | 2008-05-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7141058B2 (en) | 2002-04-19 | 2006-11-28 | Pelikan Technologies, Inc. | Method and apparatus for a body fluid sampling device using illumination |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7563232B2 (en) | 2002-04-19 | 2009-07-21 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
AU2003231749A1 (en) | 2002-04-19 | 2003-11-03 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7244265B2 (en) | 2002-04-19 | 2007-07-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7485128B2 (en) | 2002-04-19 | 2009-02-03 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7524293B2 (en) | 2002-04-19 | 2009-04-28 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US6759190B2 (en) * | 2002-06-15 | 2004-07-06 | Acon Laboratories, Inc. | Test strip for detection of analyte and methods of use |
AU2003234944A1 (en) * | 2002-08-27 | 2004-03-18 | Bayer Healthcare, Llc | Methods of Determining Glucose Concentration in Whole Blood Samples |
US7572237B2 (en) * | 2002-11-06 | 2009-08-11 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US7175897B2 (en) * | 2002-12-17 | 2007-02-13 | Avery Dennison Corporation | Adhesive articles which contain at least one hydrophilic or hydrophobic layer, method for making and uses for same |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
WO2004112602A1 (en) | 2003-06-13 | 2004-12-29 | Pelikan Technologies, Inc. | Method and apparatus for a point of care device |
US8148164B2 (en) | 2003-06-20 | 2012-04-03 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
US8679853B2 (en) | 2003-06-20 | 2014-03-25 | Roche Diagnostics Operations, Inc. | Biosensor with laser-sealed capillary space and method of making |
CA2529657C (en) | 2003-06-20 | 2011-04-12 | F. Hoffmann-La Roche Ag | Test strip with slot vent opening |
US8071030B2 (en) | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Method and apparatus for a variable user interface |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US7807043B2 (en) * | 2004-02-23 | 2010-10-05 | Oakville Hong Kong Company Limited | Microfluidic test device |
WO2006011062A2 (en) | 2004-05-20 | 2006-02-02 | Albatros Technologies Gmbh & Co. Kg | Printable hydrogel for biosensors |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
TW200718785A (en) | 2005-11-10 | 2007-05-16 | Toyo Boseki | A process for improving the thermal stability of a composition containing a soluble coenzyme conjugated glucose dehydrogenase (GDH) |
WO2009076412A1 (en) * | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Method of depositing reagent material in a test sensor |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
ES2634896T3 (en) | 2013-03-15 | 2017-09-29 | F. Hoffmann-La Roche Ag | Anti-error methods for electrochemical measurements of an analyte, as well as devices, devices and systems that incorporate them |
CN105247356B (en) | 2013-03-15 | 2017-11-07 | 豪夫迈·罗氏有限公司 | Use the method and the unit and system of merging methods described of the information of the recovery pulse in being measured from electrochemical analyte |
CA2900572C (en) | 2013-03-15 | 2018-02-13 | F. Hoffmann-La Roche Ag | Methods of detecting high antioxidant levels during electrochemical measurements and failsafing an analyte concentration therefrom as well as devices, apparatuses and systems incorporting the same |
CA2949905C (en) | 2013-03-15 | 2019-04-02 | Harvey Buck | Methods of scaling data used to construct biosensor algorithms as well as devices, apparatuses and systems incorporating the same |
PL3216076T3 (en) | 2014-11-03 | 2024-05-27 | F. Hoffmann-La Roche Ag | Method of using electrochemical test elements having multiple electrode arrangements |
EP3523639B1 (en) | 2016-10-05 | 2024-12-18 | F. Hoffmann-La Roche AG | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1598322C2 (en) * | 1967-06-30 | 1973-09-13 | Calbiochem, Los Angeles, Calif. (Vst.A.) | Laboratory reagent for the determination of glucose |
IT986838B (en) * | 1972-05-12 | 1975-01-30 | Sclavo Inst Sieroterapeut | COMPLEX OF REAGENTS FOR THE ENZYMATIC DETER MINATION OF GLUCOSE GLUCOSE SYSTEM OXIDASE PEROXIDASE DASES WITH MANUAL AND AUTOMATED METHODS CO WITH READING AT TERM OR IN KINETICS |
US4189536A (en) * | 1977-11-09 | 1980-02-19 | Hycel, Inc. | Reagent systems, enzymatic assays and compositions therefor |
CA1187388A (en) * | 1978-09-20 | 1985-05-21 | American Monitor Corporation | Stabilization of working reagent solutions containing nadh, nadph, and/or enzymes, and the use of such stabilized reagents in enzymes or substrate assays |
US4229369A (en) * | 1979-04-25 | 1980-10-21 | Hycel, Inc. | Tris (hydroxymethyl) aminomethane salt of 2-mercaptosuccinic acid |
JPS6033479B2 (en) * | 1980-07-30 | 1985-08-02 | 協和醗酵工業株式会社 | Method for quantifying hydrogen peroxide |
JPS57138389A (en) * | 1981-02-17 | 1982-08-26 | Toyobo Co Ltd | Stable urease composition |
JPS5886083A (en) * | 1981-11-12 | 1983-05-23 | Wako Pure Chem Ind Ltd | Stabilizing agent for glycerol-3-phosphoric acid oxidase |
JPS58128898A (en) * | 1982-01-26 | 1983-08-01 | Fuji Photo Film Co Ltd | Treating liquid for making offset master hydrophilic |
US4529525A (en) * | 1982-08-30 | 1985-07-16 | Colgate-Palmolive Co. | Stabilized enzyme-containing detergent compositions |
JPS59182361A (en) * | 1983-03-31 | 1984-10-17 | Kyowa Medetsukusu Kk | Determination of hydrogen peroxide |
GB8311314D0 (en) * | 1983-04-26 | 1983-06-02 | Unilever Plc | Aqueous enzyme-containing compositions |
JPS60108753A (en) * | 1983-11-18 | 1985-06-14 | Fuji Photo Film Co Ltd | Multilayer chemical analysis element |
EP0213156A1 (en) * | 1985-02-11 | 1987-03-11 | Travenol-Genentech Diagnostics | Stabilized enzyme substrate solutions |
US4900475A (en) * | 1985-07-26 | 1990-02-13 | Colgate-Palmolive Co. | Stabilized built liquid detergent composition containing enzyme |
JPS63202381A (en) * | 1987-02-17 | 1988-08-22 | Agency Of Ind Science & Technol | Stabilization of enzyme |
US5185247A (en) * | 1989-03-10 | 1993-02-09 | Miles Inc. | Stabilization of oxidase enzyme-based test strips |
US5116729A (en) * | 1989-03-10 | 1992-05-26 | Miles Inc. | Stabilization of oxidase enzyme-based test strips |
-
1994
- 1994-06-21 WO PCT/US1994/007223 patent/WO1995000662A1/en active IP Right Grant
- 1994-06-21 EP EP94920320A patent/EP0705348B1/en not_active Expired - Lifetime
- 1994-06-21 NZ NZ268301A patent/NZ268301A/en not_active IP Right Cessation
- 1994-06-21 CA CA002165663A patent/CA2165663C/en not_active Expired - Lifetime
- 1994-06-21 DE DE9422352U patent/DE9422352U1/en not_active Expired - Lifetime
- 1994-06-21 ES ES94920320T patent/ES2154249T3/en not_active Expired - Lifetime
- 1994-06-21 JP JP50312095A patent/JP3839470B2/en not_active Expired - Lifetime
- 1994-06-21 AU AU71160/94A patent/AU680520B2/en not_active Expired
- 1994-06-21 DE DE0705348T patent/DE705348T1/en active Pending
- 1994-06-21 DE DE69427911T patent/DE69427911T2/en not_active Expired - Lifetime
-
1996
- 1996-03-20 US US08/619,118 patent/US5627075A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU680520B2 (en) | 1997-07-31 |
DE9422352U1 (en) | 2000-11-09 |
ES2154249T3 (en) | 2001-12-16 |
DE69427911T2 (en) | 2002-04-04 |
NZ268301A (en) | 1997-10-24 |
DE69427911D1 (en) | 2001-09-13 |
JPH08511942A (en) | 1996-12-17 |
EP0705348A4 (en) | 1998-05-27 |
JP3839470B2 (en) | 2006-11-01 |
US5627075A (en) | 1997-05-06 |
WO1995000662A1 (en) | 1995-01-05 |
EP0705348A1 (en) | 1996-04-10 |
DE705348T1 (en) | 2000-10-05 |
AU7116094A (en) | 1995-01-17 |
EP0705348B1 (en) | 2001-08-08 |
ES2154249T1 (en) | 2001-04-01 |
CA2165663A1 (en) | 1995-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2165663C (en) | Diagnostic reagent stabilizer | |
CA2069946C (en) | Redox mediator reagent and biosensor | |
US5508171A (en) | Assay method with enzyme electrode system | |
CA2167822C (en) | Potentiometric biosensor and the method for its use | |
AU712527B2 (en) | Electrochemical biosensor test strip | |
USRE36991E (en) | Biosensor and method for producing the same | |
US5217594A (en) | Convenient determination of trace lead in whole blood and other fluids | |
EP0352925B1 (en) | Enzyme electrodes and improvements in the manufacture thereof | |
US5334296A (en) | Peroxidase colloidal gold oxidase biosensors for mediatorless glucose determination | |
CA2160905C (en) | Peroxidase colloidal gold oxidase biosensors for mediatorless glucose determination | |
Wang et al. | In situ elimination of metal inhibitory effects using ligand-containing carbon paste enzyme electrodes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140623 |